gracecast-098_lung-cancer_mm in lc pt 3: who to test and what to test for -- panel discussion
Published 12 years ago • 42 plays • Length 17:28Download video MP4
Download video MP3
Similar videos
-
16:57
gracecast-099_lung-cancer_mm in lc pt 4: broadening use of markers in practice -- panel discussion
-
6:30
stage 3 squamous lung cancer with low pd-l1 - case based panel discussion
-
17:36
gracecast-096_lung-cancer_mm in lc pt 1: dr. charles rudin on the lung cancer mutation consortium
-
6:29
case based panel discussion nsclc – does a positive her2 mutation effect treatment decisions?
-
14:17
gracecast-032_lung-cancer_intro to first line nsclc treatment
-
16:39
gracecast-067_lung-cancer_expert round table - nsclc molecular markers case 3
-
3:14
stereotactic body radiotherapy (sbrt) for oligoprogressive nsclc - onctalk lung 2023
-
5:06
case based panel discussion - egfr mutation and high pdl1 - what is the role of immunotherapy in tre
-
5:11
gracecastuc-015_lung_what is the biology of a mixed response in lung cancer?
-
6:00
case based panel discussions - egfr mutation & met - treatment decisions, level of met amplification
-
1:39
grace targeted therapies lung cancer 2021 - treatment after crizotinib in ros1 lung cancer
-
10:10
gracecast-017_lung-cancer_never-smokers with lung cancer
-
4:08
grace targeted therapies lung cancer 2021 - wait for ngs panel results - newly diagnosed, 90% pdl1
-
0:13
the importance of biomarker testing- targeted therapies in lung cancer 2023- #shorts #youtubeshorts
-
3:43
gracecast-146_lung_highlights in lung cancer, 2013: maintenance therapy in advanced nsclc
-
6:11
gracecastuc-012_lung_the more you seek, the more you find
-
15:50
gracecast-030_lung-cancer_gadgeel on advanced nsclc management
-
5:31
biomarkers in nsclc - targeted therapies in lung cancer 2023
-
9:36
gracecast-021_lung-cancer_stage iiia management options